Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Up 24.9% in April

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 2,610,000 shares, a growth of 24.9% from the March 31st total of 2,090,000 shares. Based on an average daily volume of 725,500 shares, the short-interest ratio is currently 3.6 days. Approximately 4.0% of the company’s stock are sold short.

Integra LifeSciences Stock Performance

Shares of IART traded down $0.07 during trading hours on Tuesday, reaching $29.17. 650,226 shares of the company traded hands, compared to its average volume of 702,239. The stock’s fifty day moving average is $35.02 and its 200 day moving average is $38.71. The stock has a market cap of $2.29 billion, a P/E ratio of 35.14, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 1-year low of $27.18 and a 1-year high of $56.21.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The business had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business’s revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. Equities research analysts anticipate that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC increased its stake in Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares during the period. Hexagon Capital Partners LLC grew its stake in Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after buying an additional 370 shares during the last quarter. Gladius Capital Management LP bought a new stake in Integra LifeSciences during the third quarter worth about $47,000. Valley National Advisers Inc. bought a new stake in Integra LifeSciences during the first quarter worth about $63,000. Finally, Covestor Ltd grew its stake in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after buying an additional 921 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IART. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. JMP Securities cut their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Finally, Truist Financial cut their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.